JMP Securities Reiterates Market Outperform on Terns Pharma, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Silvan Tuerkcan reiterated a Market Outperform rating on Terns Pharma (NASDAQ:TERN) and maintained a $15 price target.
April 30, 2024 | 4:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities reaffirmed a Market Outperform rating on Terns Pharma with a $15 price target.
The reiteration of a Market Outperform rating and the maintenance of a $15 price target by JMP Securities could lead to increased investor confidence in Terns Pharma, potentially driving the stock price up in the short term. The analyst's positive outlook suggests a strong belief in the company's future performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100